TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
SRPT

Sarepta Therapeutics Inc

Healthcare · Biotechnology

17.50$ +1.1% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Sarepta Therapeutics Inc (SRPT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 3,189 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SRPT
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
487 424 512 450 800 1,308 1,300 1,247 1,183 1,642 1,964 1,748 1,702 1,823 2,947 2,883 2,781 2,985 2,765 2,759 2,662 3,148 3,056 2,997 3,156 3,128 3,060 3,126 3,110 3,265 3,224 3,424 3,600 3,963 3,465 3,680 3,493 3,350 3,179 3,189
435 373 457 391 736 1,229 1,219 1,139 1,012 1,426 1,671 1,427 1,362 1,469 2,547 2,459 2,323 2,485 2,271 2,265 2,185 2,604 2,531 2,469 2,626 2,558 2,488 2,473 2,451 2,579 2,465 2,684 2,685 3,073 2,433 2,657 2,722 2,538 2,310 2,224
395 122 275 168 618 600 557 410 210 371 732 809 725 835 1,764 1,640 1,475 1,503 1,482 1,697 1,599 2,116 1,234 869 1,039 967 872 852 542 428 427 384 198 1,103 241 511 613 801 464 571
395 318 391 302 618 1,079 1,049 949 793 1,174 1,344 1,103 1,049 1,125 2,171 2,061 1,816 1,939 1,738 1,727 1,599 2,116 2,013 1,928 2,072 1,989 1,882 1,861 1,734 1,676 1,391 1,460 1,198 1,355 523 800 851 940 653 788
4.0 5.2 12 18 25 29 40 43 49 49 108 94 71 94 110 107 125 139 136 148 182 172 197 230 223 262 288 267 354 437 419 392 516 650 725 610 542 520 548 483
2.9 13 30 42 65 84 99 104 116 125 140 157 166 171 173 180 220 232 240 269 288 186 199 208 221 204 203 227 244 323 374 486 566 750 941 994 1,077 915 1,001 904
36 38 38 39 39 43 54 58 77 97 106 117 120 130 137 153 172 190 203 276 199 191 187 183 181 245 347 – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
8.1 8.1 7.7 7.8 14 14 14 15 15 12 12 12 12 12 13 13 13 14 14 14 14 14 13 13 13 7.6 7.2 18 20 30 29 28 28 27 26 31 30 29 31 31
79 87 82 72 103 519 524 548 543 610 615 649 707 1,005 1,803 1,840 1,889 2,223 2,230 2,274 2,193 2,220 2,199 2,270 2,725 2,743 2,347 2,384 2,345 2,405 2,263 2,347 2,379 2,435 2,323 2,322 2,173 2,209 1,674 1,661
65 75 75 66 70 88 91 105 114 174 137 162 216 265 306 355 378 416 365 425 373 453 455 546 603 620 537 499 451 654 609 688 699 732 606 920 921 1,095 499 503
-11 10 11 11 4.7 6.2 3.4 9.5 89 134 100 107 122 7.8 176 159 199 21 181 240 221 272 – – – 15 – 327 322 123 106 92 92 13 – – 10 11 – –
21 30 27 11 5.3 8.5 17 17 20 34 26 44 82 68 27 92 75 111 77 77 44 77 54 56 118 96 107 110 88 165 92 107 119 214 156 137 94 281 70 51
8.5 6.0 2.3 0.0 27 425 427 430 415 421 426 431 436 682 688 694 700 992 1,091 1,093 1,095 1,097 1,099 1,101 1,543 1,544 1,234 1,236 1,237 1,133 1,134 1,135 1,136 1,137 1,138 1,139 1,035 829 838 848
409 337 429 378 697 789 777 699 640 1,032 1,349 1,099 995 818 1,145 1,043 892 762 535 485 470 928 857 726 431 385 713 741 764 859 961 1,077 1,221 1,528 1,143 1,357 1,320 1,141 1,505 1,528
-1,078 -1,166 -1,082 -1,145 -1,193 -1,217 -1,252 -1,362 -1,438 -1,579 -1,656 -1,932 -2,058 -2,294 -2,311 -2,462 -2,659 -2,848 -2,955 -3,037 -3,085 -3,207 -3,312 -3,543 -3,801 -3,910 -4,427 -4,451 -4,492 -4,446 -4,410 -4,404 -4,370 -4,211 -4,658 -4,462 -4,642 -4,877 -4,546 -4,551
48 55 56 55 62 64 65 65 66 69 72 74 74 74 76 78 79 79 79 80 80 80 87 88 88 88 88 89 89 106 99 99 100 108 97 107 100 105 122 105

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?